Sugi Predict

Sugi Predict / Compounds / Methylene Chloride

Methylene Chloride

Methylene Chloride

SCHEMBL958149

ClCCl.c1ccc(P(c2ccccc2)c2ccccc2)cc1

nearest known ligand 0.75

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 1/20 0.75
▸ TDP1 Q9NUW8 1/20 0.75
▸ ESR1 P03372 4/20 0.55
▸ ESR2 Q92731 4/20 0.55
▸ KDM4E B2RXH2 1/20 0.42
▸ GAA P10253 1/20 0.42
▸ TSHR P16473 1/20 0.35
▸ ALDH1A1 P00352 3/20 0.35
▸ GSK3B P49841 2/20 0.35
▸ TRPA1 O75762 1/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ HIF1A Q16665 1/20 0.35
▸ NPSR1 Q6W5P4 2/20 0.33
▸ CALM1 P0DP23 1/20 0.33
▸ DRD1 P21728 2/20 0.32
▸ CYP19A1 P11511 1/20 0.32
▸ CES2 O00748 1/20 0.32
▸ CES1 P23141 1/20 0.32
▸ LMNA P02545 2/20 0.32
▸ HTT P42858 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methylene Chloride SCHEMBL17511253 0.94 CYP3A4 (0.67) CYP3A4TDP1ESR1ESR2KDM4E
Methylene Chloride SCHEMBL3967586 0.92 CYP3A4 (0.63) CYP3A4TDP1ESR1ESR2KDM4E
Ethyl Chloride SCHEMBL2149959 0.88 CYP3A4 (0.67) CYP3A4TDP1ESR1ESR2KDM4E
SCHEMBL5356053 0.88 TDP1 (0.67) CYP3A4TDP1ESR1ESR2KDM4E
SCHEMBL3181354 0.87 TDP1 (0.86) CYP3A4TDP1ESR1ESR2KDM4E
SCHEMBL561726 0.87 TDP1 (0.86) CYP3A4TDP1ESR1ESR2KDM4E
SCHEMBL81285 0.87 TDP1 (0.86) CYP3A4TDP1ESR1ESR2KDM4E
SCHEMBL9420677 0.87 TDP1 (0.86) CYP3A4TDP1ESR1ESR2KDM4E
SCHEMBL1951204 0.87 TDP1 (0.86) CYP3A4TDP1ESR1ESR2KDM4E
SCHEMBL5028587 0.87 TDP1 (1.00) CYP3A4TDP1ESR1ESR2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108837845-A A kind of basic catalyst and preparation method and application of anti-hydrogen chloride 浙江工业大学 2018-11-20 — — CN claimed
US-5665802-A REACTING POLYAMIC ACID WITH A DEHYDRATION-CYCLIZATION AGENT, A CATALYST AND AN ORGANIC PHOSPHORUS COMPOUND; EXCELLENT IN TENSILE STRENGTH AND FLEXIBILITY KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1997-09-09 — — US claimed
WO-2025200154-A1 TWO-PART EPOXY COMPOSITION COMPRISING THIOL CURATIVE, AND CATALYST 3M INNOVATIVE PROPERTIES COMPANY (US) 2025-10-02 — — WO disclosed
CN-116730870-B Hydroxamic acid compound or pharmaceutically acceptable salt thereof, application and preparation method thereof 中国医学科学院医药生物技术研究所 2023-10-13 — — CN disclosed
CN-116730870-A Hydroxamic acid compound or pharmaceutically acceptable salt thereof, application and preparation method thereof 中国医学科学院医药生物技术研究所 2023-09-12 — — CN disclosed
US-20230095223-A1 SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2023-03-30 — — US disclosed
CN-113166618-B Adhesive composition and surface protective film DIC株式会社 2022-08-23 — — CN disclosed
US-11185592-B2 Spirocyclic degronimers for target protein degradation C4 THERAPEUTICS, INC. (US) 2021-11-30 — — US disclosed
CN-113166618-A Adhesive composition and surface protective film DIC株式会社 2021-07-23 — — CN disclosed
US-20210106688-A1 SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2021-04-15 — — US disclosed
CN-111712507-A Method for improving oral bioavailability of drugs 药物有限公司 2020-09-25 — — CN disclosed
EP-0350958-B1 Improved polyimide and polyimide film and manufacturing method thereof KANEGAFUCHI CHEMICAL IND (JP) 1994-12-21 — — EP disclosed
US-5116981-A Antiinflammatory leukotriene B4 analogs THE UPJOHN COMPANY (US) 1992-05-26 — — US disclosed
US-4925834-A FERTILITY CONTROL, ANTITUMOR AGENTS SCHERING AKTIENGESELLSCHAFT (DE) 1990-05-15 — — US disclosed
EP-0350958-A2 Improved polyimide and polyimide film and manufacturing method thereof KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1990-01-17 — — EP disclosed
EP-0339046-A1 LEUKOTRIENE B 4? ANALOGS. UPJOHN CO (US) 1989-11-02 — — EP disclosed
CN-85108698-B Process for preparing N-substituted aziridine-2-carboxylic acid and derivatives thereof 曼海姆泊灵格股份公司 1988-09-07 — — CN disclosed
WO-1988005045-A1 LEUKOTRIENE B4 ANALOGS THE UPJOHN COMPANY (US) 1988-07-14 — — WO disclosed
CN-85108698-A The preparation method and the application thereof of N-substituted aziridine-2-carboxylic acid — 1986-07-23 — — CN disclosed
US-4322416-A ENZYME INHIBITORS OF OXIDOREDUCTASES; ANTIESTROGENS; ANTIFERTILITY AGENTS MERRELL DOW PHARMACEUTICALS INC. (US) 1982-03-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11185592-B2 Spirocyclic degronimers for target protein degradation STUB1, UBE3C, UBE3A CYP3A4 3106/4885TDP1 3690/4885ESR1 233/4885
US-20210106688-A1 SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION STUB1, UBE3C, UBE3A CYP3A4 3106/4885TDP1 3690/4885ESR1 233/4885
US-20230095223-A1 SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION STUB1, UBE3C, UBE3A CYP3A4 3106/4885TDP1 3690/4885ESR1 233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.